Document:

EXHIBIT 10.01

 

AGREEMENT AND PLAN OF MERGER 

 

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”)
is made and entered into this 8th day of February, 2016, by and between Nexeon MedSystems, Inc., a Delaware Corporation (“NXDE”),
and Nexeon MedSystems Inc, a Nevada corporation (“NXNV”). Together, NXDE and NXNV are the “Parties”.

 

Recitals

 

A. NXDE is a corporation duly organized and
validly existing under the laws of the State of Delaware and, as of the date hereof, has authorized capital consisting of 17,000,000
shares of Common Stock with a par value of $0.0001 per share, of which 1,529,000 shares are issued and outstanding; and 14,000,000
shares of Preferred Stock par value $0.0001 per share, of which 10,222,137 shares of Series A Preferred Shares, and 832,034 shares
of Series B Preferred Shares are issued and outstanding. Additionally, NXDE has 80,000 outstanding options which shall be[1]
terminated at the Effective Time and 604,212 Deferred Compensation Units outstanding, all of which will be terminated[2]
at the Effective Time.

 

B. NXNV is a corporation duly organized and
validly existing under the laws of the State of Nevada and, as of the date hereof, has authorized capital consisting of 75,000,000
shares of Common Stock with a par value of $.001 per share, of which 15,000,000 shares are issued and outstanding.

 

C. Each Party’s Board of Directors believes
it is in its and its stockholders’ best interests that NXDE merge with and into NXNV through a statutory merger (the “Merger”)
and, in furtherance thereof, have approved the Merger.

 

D. Pursuant to the Merger all of NXDE’s
issued and outstanding shares of (i) Series A Preferred Stock (the “Series A Preferred Shares”), and (ii)
Series B Preferred Stock (the “Series B Preferred Shares” and, together with the Series A Preferred Stock,
the “NXDE Preferred Shares”, each having a par value of $0.0001 per share, will be converted into
the right to receive shares of NXNV Common Stock, par value $0.001 per share (“NXNV Common Shares”).

 

 

Now, Therefore, for and in consideration of
the mutual covenants and agreements hereinafter set forth and other good and valuable consideration, the receipt, adequacy and
sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

Definitions

 

“Material Adverse Effect”
or “Material Adverse Change” means any effect or change that would be materially adverse to the business of
either Party or to the ability of any Party to consummate timely the transactions contemplated hereby: provided, that none of the
following shall be deemed to constitute and none of the following shall be taken into account in determining whether there has
been a Material Adverse Effect or Material Adverse Change: (a) any adverse change, event, development or effect arising from or
relating to (1) general business or economic conditions, including such conditions related to the business of the either Party,
(2), national or international social or political conditions, including the engagement of the United States in hostilities, whether
or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack on the
United States, or any of its territories, possessions or diplomatic or consular offices or upon the military installation, equipment
or personnel of the United States, (3) financial, banking or securities markets (including any disruption thereof and any decline
in the price of any security or market index, (4) changes in GAAP, (5) changes in laws, rules, regulations, orders or other binding
directives issued by any Government Authority or (6) the taking of any action contemplated by this Agreement and any agreements
contemplated hereby; (b) any existing event, occurrence or circumstances with respect to which NXNV and NXDE have actual knowledge
as of the date hereof; and (c) any adverse change in or effect of the business of the Company that is cured by the Effective Time
or the termination of this Agreement.

 

    	1

    	 

    

 

“Net Product Sales ”means
all cash and non-cash consideration from the sale of Products less the following items directly attributable to the Sale of such
Products and borne by Surviving Corporation (as defined below), its affiliates or licensees as the seller: (a) discounts and rebates
actually granted; (b) sales, value added, use and other taxes and government charges actually paid, excluding income taxes; (c)
import and export duties actually paid; (d) freight, transport, packing and transit insurance charges actually paid or allowed;
and (e) other amounts actually refunded, allowed or credited due to rejections or returns, but not exceeding the original invoiced
amount.

 

“Patents” means (a) the
patents and patent applications listed on Exhibit A, all patents resulting from the patent applications listed on Exhibit
A, and all continuations, continuations-in-part, divisions, extensions, substitutions, re-issues, re-examinations, and renewals
of any of the foregoing, and (b) any patents arising from any applications filed after the Effective Time and that claim priority
from any of the patents or patent applications in subsection (a) priority.

 

“Person” means an individual,
a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture and
unincorporated organization, and any other business entity or Governmental Authority.

 

“Products” means all products
developed by the Surviving Corporation using the Patents.

 

“Quarterly Payment Deadline”
means the day that is 30 days after the last day of any particular Quarter.

 

“Sell, Sale or Sold” means
any transfer or other disposition of Products or for which consideration is received by the Surviving Corporation, its affiliates
or licensees. A Sale of Products will be deemed completed at the time the Surviving Corporation or its affiliates or licensees
receives such compensation. On or before each Quarterly Payment Deadline, Surviving Corporation shall report to the entity formed
by NXDE to receive royalty payments the identification of each Product for which royalty payments are due in that quarter, the
name of any licensee or affiliate making such sales, the Net Product Sales proceeds received in that quarter by Surviving Corporation,
its licensees and affiliates, and the royalties due from such sales.

 

    	2

    	 

    

 

Merger

 

§ 1.1 Surviving Corporation. In
accordance with the terms and conditions of this Agreement, including without limitation, the conditions precedent set forth in
Article VI hereof, NXDE shall be merged with and into NXNV (the “Merger”) effective as of the Effective Time (as defined
in 1.2 below). NXNV shall be the surviving corporate entity (the “Surviving Corporation”) and shall continue its corporate
existence under the laws of the State of Nevada. The name of the Surviving Corporation shall continue to be “Nexeon MedSystems
Inc”, a Nevada corporation.

 

§ 1.2 Effective Time. The Parties
will cause the Merger to be consummated by filing a Certificate of Merger (or like instrument) with the Secretary of State of Delaware
and the Nevada Secretary of State in accordance with the corporate laws of the State of Delaware and Nevada. The Merger shall become
effective upon the issuance of a Certificate of Merger by the Nevada Secretary of State. The date and time when the Merger becomes
effective is referred to herein as the “Effective Time.”

 

§ 1.3 Succession and Assumption.
Immediately as of the Effective Time, by virtue of the Merger and without any action by NXNV or NXDE: (a) NXNV shall succeed to
all present and future rights, titles, privileges, powers and franchises of NXNV and NXDE, and (b) NXNV shall assume any and all
liabilities, duties and obligations of NXDE and NXNV, as they exist immediately prior to the Effective Time.

 

§ 1.4 Articles of Incorporation.
As of the Effective Time, the Articles of Incorporation of NXNV in effect immediately prior to the Effective Time shall become
the Articles of Incorporation of the Surviving Corporation, until thereafter amended as provided by law.

 

§ 1.5 Bylaws. At the Effective
Time, the Bylaws of NXNV in effect immediately prior to the Effective Time shall become the Bylaws of the Surviving Corporation,
until thereafter amended as provided by law.

 

§ 1.6 Officers and Directors. At
the Effective Time, the directors of NXNV shall consist of five members: two (2) of the directors shall be appointed by the former
directors of NXDE, one of whom shall be Dr. Mark Bates with the other to be a yet to be determined individual; and three (3) of
the directors shall have be elected by NXNV shareholders, who shall be William Rosellini, Ronald Conquest, and a yet to be determined
individual. Thereafter, the full board of directors shall elect the officers of NXNV.

 

Conversion of Stock

 

§ 2.1 Conversion of Stock. At the
Effective Time, by virtue of the Merger and without any action on the part of the holders thereof:

 

(a) the number of shares of Common Stock of
NXNV, $0.001 par value per share (the “NXNV Common Stock”), authorized immediately prior to the Effective Time shall
continue to represent the same number of authorized shares of the Surviving Corporation Common Stock; the number of shares of Preferred
Stock of NXNV, $0.001 par value per share (the “NXNV Preferred Stock”) authorized prior to the Effective Time shall
continue to represent the same number of authorized shares of the Surviving Corporation Preferred Stock; and

 

    	3

    	 

    

 

(b) the total number of shares of the NXDE
Preferred Shares issued and outstanding prior to the Effective Time, shall be converted into the right to receive 1,659.943 fully
paid and non-assessable NXNV Common Stock (the “Preferred Conversion Consideration”). No such shares of NXDE Preferred
Shares shall be converted to Preferred Stock of the Surviving Corporation. The total number of shares received in the Merger, shall
be allocated to each NXDE Shareholder pursuant to the list of current NXDE shareholders. The list of those NXDE shareholders, along
with the number of shares of NXNV Common Stock, which each NXDE Shareholder will receive, is attached hereto as Exhibit B. Each
share of NXDE’s Common Shares issued and outstanding immediately prior to the Effective Time will be cancelled and extinguished
without conversion.

 

(c) all such NXDE Preferred Shares, when so
converted, will no longer be outstanding and will automatically be canceled and retired and will cease to exist, and the holder
of a certificate (“NXDE Preferred Stock Certificate”) that, immediately prior to the Effective Time,
represented outstanding NXDE Preferred Shares will cease to have any rights with respect thereto, except the right to receive,
upon the surrender of such NXDE Preferred Stock Certificate: (i) the Preferred Conversion Consideration, and (ii) cash in lieu
of fractional shares under Section ‎2.2 (collectively, the “Merger Consideration”).

 

§ 2.2 Fractional Shares. In lieu
of issuing fractional shares of the Surviving Corporation in exchange for NXDE Stock, the Surviving Corporation shall cause to
be paid to each person or entity entitled thereto an amount equal to $1.00 for each fractional share of the Surviving Corporation’s
Common Stock resulting from the conversion of NXDE Stock into stock of the Surviving Corporation pursuant to §2.1 hereof.

 

§ 2.3 Closing of Transfer Books.
At the Effective Time, the stock transfer books of NXNV and NXDE shall be closed and no transfer of shares of NXDE shall thereafter
be made. After the Effective Time, certificates previously representing shares of NXDE Common Stock and shares of both Series A
and Series B NXDE Preferred Stock shall be cancelled and exchanged for shares of Common Stock of the Surviving Corporation as provided
in §2.4 hereof.

 

§ 2.4 Exchange of NXDE Stock. As
soon as practicable after the Effective Time, the Surviving Corporation shall mail to each holder of record of NXDE Stock, immediately
prior to the Effective Time, a form letter of transmittal for return to the Surviving Corporation, or its stock transfer Agent,
containing instructions for use in effecting the surrender of certificates of NXDE Stock for certificates of Common Stock in the
Surviving Corporation. Upon the proper surrender of such certificates, the record holder thereof shall be issued the number of
fully paid and non-assessable shares of the Surviving Corporation’s Common Stock as such holder is entitled to receive under
§§2.1 and 2.2 hereof. Thereafter such NXDE surrendered certificates shall be cancelled and of no further force or effect.
Until surrendered, each certificate of NXDE Stock shall represent solely the right to receive shares of the Surviving Corporation
into which the NXDE Stock shall have been converted pursuant to §§2.1 and 2.2 hereof.

 

NXDE and its Shareholders understand and
accept without qualification that the shares of NXNV Common Stock received pursuant to this Agreement have not been registered
with the Securities and Exchange Commission (SEC) or any state securities regulatory authority, and that standard restrictions
on the unregistered shares of NXNV Common Stock will apply to each and every NXDE Shareholder receiving shares a part of this Merger
or Debt Conversion. Each Stock Certificate issued by NXNV shall bear a legend indicating that the shares are non-transferrable
until the standard NXNV and SEC conditions for enabling transferability have been met.

 

    	4

    	 

    

 

§ 2.5 Dissenting Shares. Any holders
of shares of NXDE Stock outstanding immediately prior to the Effective Time who have properly perfected their statutory dissenters
rights in accordance with Section 262 of The Business Corporation Law of Delaware shall receive payment for their shares after
the Effective Time from the Surviving Corporation, but only after the amount of such payment has been agreed upon or finally determined
pursuant to such provisions of Section 262 of Business Corporation Law of Delaware.

 

§ 2.6 Additional Consideration.
Prior to the Effective Time, NXDE shall spin-off any rights to the royalties in this Section 2.6 to a newly formed limited liability
company (“NXDE LLC”). As additional consideration to the shareholders of NXDE, the Surviving Corporation shall pay
NXDE LLC a royalty equal to Three Percent (3%) (the “NXDE Royalty”) of Net Product Sales received by the Surviving
Corporation, its affiliates and licensees after the merger and derived from the commercialization of patents or other intellectual
property owned by NXDE prior to the merger. A comprehensive list, agreed to by NXNV and NXDE of any and all such patents and intellectual
property is attached hereto as Exhibit A and by this reference incorporated herein.

 

§ 2.7 Tax Treatment. The Parties
intend that the Merger constitute a tax free reorganization under Code Section 368.

 

§ 2.8 Conversion/Assumption/Payment
of Certain Notes Payable to Stockholders. At the Effective Time, any NXDE shareholder owed any sum of money by NXDE shall have
the right to convert their debt to participation in the NXNV Private Placement dated February 1, 2016 (the “Offering”)
pursuant to the terms and conditions of the Offering as set forth in the NXNV Private Placement Memorandum. The debt exchange rate
shall be One Dollar ($1.00) of NXDE shareholder debt for One (1) Unit of the Offering. Any amount owed to an NXDE shareholder not
converted into shares of NXNV Common Stock shall be represented by a promissory note entered into at the Effective Time by and
between NXNV and the NXDE shareholder or their affiliates. The principal and interest of the promissory note shall be due and payable
Two (2) years from the Effective Date and shall accrue interest at the rate of Seven Percent (7%) per annum.

 

Representations and Warranties of NXDE

 

NXDE hereby represents and warrants to NXNV
as follows:

 

§ 3.1 Corporate Organization. NXDE
is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware with all requisite
corporate power and authority to own, operate and lease its properties and to carry on its business as it is now being conducted.

 

§ 3.2 Capitalization of NXDE. As
of the date hereof, the authorized capital stock of NXDE consists of 17,000,000 shares of Common Stock, par value of $0.0001 per
share, of which there are issued and outstanding 1,529,000 shares of such Common Stock. As of the date hereof, the authorized capital
stock of NXDE consists of 14,000,000 shares of Preferred Stock, par value of $0.0001 per share, of which there are issued and outstanding
10,222,137 shares of Series A Preferred Stock and 832,034 shares of Series B Preferred Stock. All of such outstanding shares have
been validly issued and are fully paid and non-assessable with no personal liability attaching to the ownership thereof. Prior
to the Effective Time, there were 80,000 Stock Options, all of which will be terminated at or prior to the Effective Time and 604,212
Deferred Compensation Units of NXDE, all of which will be terminated at the Effective Time.

 

    	5

    	 

    

 

§ 3.3 Authorization. NXDE has the
necessary corporate power and authority to enter into this Agreement, which has been duly authorized by its board of directors
and shareholders. This Agreement is a legal, valid, and binding obligation of NXDE.

 

§ 3.4 No Violation. Neither the
execution and delivery of this Agreement by NXDE, the performance by NXDE of its obligations hereunder nor the consummation by
it of the transactions contemplated hereby will (i) violate any provision of the Articles of Incorporation or Bylaws of NXDE; (ii)
constitute a default under or cause the acceleration of the maturity of any debt or obligation, which, individually or in the aggregate
with all other such debts and obligations, is material to NXDE taken as a whole; or (iii) to the best of the knowledge and belief
of NXDE, violate any statute or law or any judgment, decree, order, regulation or rule of any court or governmental authority to
which NXDE is subject, which would have a material adverse effect on the financial condition, business, or operations of NXDE,
taken as a whole.

 

§ 3.5 Litigation. Except as set
forth on Schedule 3.5[3], to the best
of the knowledge and belief of NXDE, there is no action, proceeding or investigation pending or threatened against or involving
NXDE or any properties or rights of NXDE, to specifically include any patents issued or pending in which NXDE has an ownership
interest, which, if determined adversely, could materially and adversely affect the financial condition, business, or operations
of NXDE taken as a whole. NXDE is not in violation of any order, judgment, injunction, or decree outstanding against it, the effect
of which would be materially adverse to the financial condition, business, or operations of NXDE, taken as a whole.

 

§ 3.6 Financial Statements. NXDE
heretofore has delivered to NXNV true and complete copies of the audited historical consolidated financial statements of NXDE as
of December 31, 2010 and the unaudited consolidated financial statements for the periods ending December 31, 2011 through December
31, 2015. Such financial statements of NXDE delivered to NXNV were prepared in accordance with generally accepted accounting principles
applied on a consistent basis and present fairly the financial position, results of operations, and changes in financial position
of NXDE as of the dates and for the periods indicated herein above. As of the date of such financial statements, NXDE did not have
any liabilities or obligations (absolute, accrued, contingent or otherwise) material to NXDE taken as a whole, which were not reflected
on such financial statements. Since the date of such financial statements, NXDE has not incurred any liabilities material to NXDE
taken as a whole, except (i) liabilities incurred in the ordinary course of business and consistent with past practices; (ii) liabilities
disclosed on such financial statements; and (iii) liabilities incurred in connection with this Merger or as otherwise permitted
by this Agreement.

 

    	6

    	 

    

 

§ 3.7 Title to Properties. NXDE
has good and marketable title to any and all of its material properties and assets (real, person and mixed, tangible and intangible)
including without limitation, all the properties and assets which it purports to own as reflected on its financial statements furnished
to NXNV, and specifically with respect to patents issued or pending in which NXDE has an ownership interest.

 

§ 3.8 No ERISA Issues. NXDE has
no plan or agreement filed under the Employment Retirement Income Security Act which will cause any assumed or ongoing liability
to Surviving Corporation.

 

Representations and Warranties of NXNV

 

NXNV hereby represents and warrants to NXDE
as follows:

 

§ 4.1 Corporate Organization. NXNV
is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada with all requisite
corporate power and authority to own, operate, and lease its properties and to carry on its business as it is now being conducted.

 

§ 4.2 Capitalization of NXNV. As
of the date hereof, the authorized capital stock of NXNV consists of 75,000,000 shares of Common Stock, par value of $0.001 per
share, and there are 15,500,000 shares Common stock issued and outstanding, and there are no shares of Preferred Stock authorized
or issued and outstanding. All of such outstanding shares have been validly issued and are fully paid and non-assessable with no
personal liability attaching to the ownership thereof. As of the date hereof, there are no outstanding options, warrants, subscriptions,
or other rights obligating of NXNV to issue any shares of its capital stock or other securities convertible into any shares of
its capital stock.

 

§ 4.3 Authorization. NXNV has the
necessary corporate power and authority to enter into this Agreement and this Agreement has been duly authorized by its board of
directors and shareholders. This Agreement is a legal, valid, and binding obligation of NXNV.

 

§ 4.4 No Violation. Neither the
execution and delivery of this Agreement by NXNV, the performance by NXNV of its obligations hereunder nor the consummation by
it of the transactions contemplated hereby will: (i) violate any provision of the Articles of Incorporation or Bylaws of NXNV;
(ii) constitute a default under or cause the acceleration of the maturity of any debt or obligation, which, individually or in
the aggregate with all other such debts and obligations, is material to NXNV, taken as a whole; or (iii) to the best knowledge
of NXNV, violate any statute or law or any judgment, decree, order, regulation, or rule of any court or governmental authority
to which NXNV is subject, which would have a material adverse effect on the financial condition, business, or operations of NXNV,
taken as a whole.

 

§ 4.5 Litigation. To the best of
the knowledge and belief of NXNV, there is no action, proceeding or investigation pending or threatened against or involving NXNV
or any properties or rights of NXNV, which, if determined adversely, could materially and adversely affect the financial condition,
business, or operations of NXNV, taken as a whole. NXNV is not in violation of any order, judgment, injunction or decree outstanding
against it the effect of which would be materially adverse to the financial condition, business, or operations of NXNV, taken as
a whole.

 

    	7

    	 

    

 

§ 4.6 Financial Statements. NXNV
heretofore has delivered to NXDE true and complete copies of its balance sheet as of December 7, 2015 and a Performa balance sheet
as of January 2, 2016. Such financial statements of NXNV delivered to NXDE were prepared in accordance with generally accepted
accounting principles applied on a consistent basis and present fairly the financial position, and changes in financial position
of NXNV as of the dates and for the periods set forth herein above. As of the date of such financial statements, NXNV did not have
any liabilities or obligations (absolute, accrued, contingent or otherwise) material to NXNV, taken as a whole, which were not
reflected on such financial statements. Since the date of such financial statements, NXNV has not incurred any liabilities material
to NXNV, taken as a whole, except: (i) liabilities incurred in the ordinary course of business and consistent with past practices;
(ii) liabilities disclosed on such financial statements; and (iii) liabilities incurred in connection with this Merger or as otherwise
permitted by this Agreement.

 

§ 4.7 Title to Properties. NXNV
has good and marketable title to any and all of its material properties and assets (real, person and mixed, tangible and intangible)
including without limitation, all the properties and assets, which it purports to own as reflected on its financial statements
furnished to NXDE.

 

Covenants

 

§ 5.1 Conduct of Business Prior to
the Effective Time. Each of NXNV and NXDE agrees that prior to the Effective Time:

 

(a) each of their respective businesses shall
be conducted only in the ordinary course;

 

(b) except as required in connection with this
Merger, it shall not: (i) amend its Articles of Incorporation or Bylaws; (ii) change the number of authorized shares of its capital
stock; or (iii) declare, set aside, or pay any dividend or other distribution or payment in cash, stock, or property in respect
of the shares of its capital stock;

 

(c) it shall not: (i) issue, grant or sell
any shares or rights of any kind to acquire any shares of its capital stock; (ii) acquire any assets or enter into any other transaction,
other than in the ordinary course of business; (iii) dispose of, encumber or mortgage any assets or properties which are material
to it taken as a whole other than in the ordinary course of business; (iv) waive, release, grant or transfer any rights of value
or modify or change in any material respect any existing license, lease, contract or other document other than in the ordinary
course of business; or (v) enter into any contract, agreement, commitment or arrangement with respect to any of the foregoing;
and

 

(d) it shall use its best efforts to preserve
intact its business organization, to keep available the service of its present officers and key employees, and to preserve the
goodwill of those having business relationships with it.

 

§ 5.2 Compliance with Laws. Each
of NXNV and NXDE shall duly comply in all material respects with all laws applicable to it and its properties, operations, business
and assets.

 

§ 5.3 Access to Properties and Records.
Each of NXNV and NXDE shall, upon reasonable request, afford to the other's accountants, counsel and other authorized representatives,
full access during normal business hours throughout the period prior to the Effective Time to all of its properties, books, contracts,
commitments and records.

 

    	8

    	 

    

 

§ 5.4 Further Actions. Subject
to the terms and conditions hereof, NXNV and NXDE each agree to use all reasonable efforts to take, or cause to be taken, all action
and to do, or cause to be done, all things necessary, proper or advisable to consummate and make effective the transactions contemplated
by this Agreement, including without limitation, using all reasonable efforts: (i) to obtain all necessary waivers, consents and
approvals, to give all notices and to effect all necessary registrations and filings; and (ii) to defend any lawsuits or other
legal proceedings, whether judicial or administrative and whether brought derivatively or on behalf of third parties challenging
this Agreement or the consummation of the transactions contemplated hereby.

 

Conditions Precedent

 

§ 6.1 Conditions to the Obligation
of NXDE to Effect this Merger. Each and every obligation of NXDE under this Agreement to be performed on or before the Effective
Time shall be subject to the fulfillment by NXNV of the following additional conditions:

 

(a) NXNV shall have performed in all material
respects its obligations under this Agreement required to be performed by it on or prior to the Effective Time pursuant to the
terms hereof;

 

(b) the representations and warranties of NXNV
contained in this Agreement shall be true and correct in all material respects at and as of the Effective Time as if made at and
as of such time, except as affected by the transactions contemplated hereby;

 

(c) there shall have been no material adverse
change in the business, assets, financial condition or results of operations of NXNV, taken as a whole, since the date of the financial
statements furnished to NXDE;

 

(d) NXNV shall have furnished such certificates
of its officers to evidence its compliance with the conditions set forth herein as may be reasonably requested by NXDE;

 

(e) the shareholders of NXDE shall have approved
the Merger; and

 

(f) NXNV shall have executed and delivered
to NXDE LLC that certain Royalty Agreement covering the NXDE Royalty in the form attached hereto as Exhibit D.

 

§ 6.2 Conditions to the Obligation
of NXNV to Effect this Merger. Each and every obligation of NXNV under this Agreement to be performed on or before the Effective
Time shall be subject to the fulfillment by NXNV of the following additional conditions:

 

(a) NXDE shall have performed in all material
respects its obligations under this Agreement required to be performed by it on or prior to the Effective Time pursuant to the
terms hereof;

 

(b) the representations and warranties of NXDE
contained in this Agreement shall be true and correct in all material respects at and as of the Effective Time as if made at and
as of such time, except as affected by the transactions contemplated hereby;

 

    	9

    	 

    

 

(c) there shall have been no material adverse
change in the business, assets, financial condition or results of operations of NXDE taken as a whole since the date of the financial
statements furnished to NXNV, the conversion of debt to NXNV shares of Common Stock prior to or simultaneous to the Effective Time
notwithstanding;

 

(d) NXDE shall have furnished such certificates
of its officers to evidence its compliance with the conditions set forth herein as may be reasonably requested by NXNV.

 

(e) NXDE shall have delivered to NXNV all books
and records necessary to accomplish the transfer of all assets owned by NXDE prior to the merger, including without limitation
all accounting and intellectual property hard and electronic files.

 

(f) NXDE shall have terminated any and all
options, warrants, deferred compensation units, issued and outstanding immediately prior to the Effective Time, and any and all
other rights to equity of any kind or nature whatsoever of NXDE,

 

(g) at the Effective Time, Mark Bakes shall
convert any and all debt owed to him by NXDE to shares of NXNV’s Common Stock and Ralph Ballard and his affiliates shall
convert any and all debt, less the sum of $150,000, owed to him and his affiliates by NXDE to shares of NXNV’s Common Stock.
At the Effective Time, Ralph Ballard shall receive a promissory note in the amount of $150,000 payable to him or his affiliates
by NXNV on terms acceptable to both parties.

 

Termination

 

§ 7.1 Termination. This Agreement
may be terminated if and only if the NXNV and NXDE Shareholders fail to approve this Agreement.

 

§ 7.2 Effect of Termination. In
the event of the termination of this Agreement by either NXNV or NXDE, as provided above:

 

(a) this Agreement shall be void and of no
further effect, and there shall be no liability by reason of this Agreement or the termination thereof on the part of either NXNV
or NXDE, or on the part of their respective directors, officers, employees, agents or shareholders; and

 

(b) all information received by either party
hereto with respect to the business of the other party or its divisions, affiliates or associates (other than information which
is a matter of public knowledge or which has heretofore been or is hereafter published in any publication for public distribution
or filed as public information with any governmental authority) shall not at any time be used for the advantage of, or disclosed
to third parties for any reason whatsoever.

 

Miscellaneous

 

§ 8.1 Amendment. This Agreement
may be amended by the parties hereto by action taken by their respective board of directors at any time prior to the Effective
Time, but no such amendment shall (i) alter the amount or change the form of consideration into which shares of NXDE Stock are
to be converted as provided in 2.1 and 2.2 hereof, or (ii) alter or change any of the terms and conditions of this Agreement if
such alteration or change would adversely affect the holders of any class of capital stock of NXNV or NXDE. This Agreement may
not be amended except by an instrument in writing signed on behalf of each of the parties hereto.

 

    	10

    	 

    

 

§ 8.2 Fees and Expenses. Except
as otherwise provided herein, the parties hereto shall bear their own costs and expenses incurred in connection herewith and with
the transactions contemplated hereby, whether the Effective Time occurs or this Agreement shall be terminated. NXNV and NXDE agree
to indemnify and hold the other harmless from any claim (together with costs and expenses, including attorneys fees, incurred in
connection with such claims) for compensation by any person, firm or corporation claiming to have been requested, authorized or
employed to act as lender, broker or agent in connection with the subject matter of this Agreement or negotiations leading thereto.

 

§ 8.3 Assignment. No party shall
assign this Agreement or any of its rights and obligations hereunder without the prior written consent of the other party.

 

§ 8.4 Successors and Assigns. This
Agreement shall be binding upon and inure to the benefit of the parties hereto, their heirs, legal representatives, successors
and permitted assigns.

 

§ 8.5 Notices. Any notice, demand
or request required or permitted to be given under any provision of this Agreement shall be in writing and delivered personally
or by registered or certified mail (return receipt requested, with postage prepaid) to the following address, or to such other
address as either party may request by notice in writing to the other party:

 

		(a)	If to NXNV:

 

Mr. Ron Conquest, COO

Nexeon MedSystems Inc

1708 Jaggie Fox Way

Lexington, KY 40511

480-203-9999

 

		(b)	If to NXDE:

 

Dr. Mark Bates, M.D., Director

C/O Ms. Amy J. Tawney, Esq

600 Quamer Street

Charleston, WV 25301

304-347-1123

 

§ 8.6 Entire Agreement. This Agreement
constitutes the entire agreement and understanding of the parties with respect to the subject matter hereof, superseding any and
all prior agreements, understandings, negotiations and discussions. No amendment, alteration, modification or waiver of this Agreement
shall be binding unless evidenced by an instrument in writing signed on behalf of each of the parties hereto.

 

§ 8.7 Construction. The captions
and headings of this Agreement are for convenience and reference only, and shall not control or affect the meaning or construction
of this Agreement. Use of the masculine gender shall also be deemed to refer to the feminine gender and neuter gender and the singular
to the plural unless the context clearly requires otherwise.

 

    	11

    	 

    

 

§ 8.8 Choice of Law. This Agreement
shall be construed, governed, and enforced in accordance with the laws of the State of Nevada.

 

§ 8.9 Severability. The invalidity
or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision hereof
and this Agreement shall be construed in all respects as if such invalid or unenforceable provision was omitted. The invalidity
or unenforceability of any provision of this Agreement to any person or circumstance shall not affect the validity or enforceability
of such provision as it may apply to any other persons or circumstances.

 

§ 8.10 Waiver. The failure in one
or more instances of a party to insist upon performance of any of the terms, conditions and covenants set forth in this Agreement,
or the failure of a party to exercise any right or privilege conferred by this Agreement, shall not be construed thereafter as
waiving their right to insist upon the performance of such terms, conditions and covenants or the right to exercise such rights
and privileges, which rights shall continue and remain in full force and effect as if no forbearance had occurred.

 

§ 8.11 Attorney Fees. In the event
it becomes necessary for either party to file a suit to enforce this Agreement or any provision contained herein, and either party
prevails in such action, then such party shall be entitled to recover, in addition to all other remedies or damages, reasonable
attorney fees and court costs incurred in such suit.

 

§ 8.12 Counterparts. This Agreement
may be executed in any number of counterparts, each of which shall be deemed an original instrument, but all of which together
will constitute for all purposes one and the same instrument.

 

§ 8.13 Construction. The Parties
have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or
interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof
shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. Any reference
to any federal, state, local or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereby,
unless the context requires otherwise. The word “including” shall mean including without limitation.

 

In Witness Whereof, the parties hereto
have executed this Agreement as of the date first above written.

 

	  	 	
        NEXEON MEDSYSTEMS, INC., a Delaware corporation

	 	 	 
	Attest:	 	
        By:

         

        /s/ Mark Bates

	  	 	Dr. Mark Bates, M.D., CEO
	/s/	 	 
	Secretary	 	 

 

    	12

    	 

    

 

	  	 	NEXEON MEDSYSTEMS INC, a Nevada corporation
	  	 	 
	Attest:	 	
        By:

         

        /s/ William Rosellini

        

	  	 	William Rosellini, CEO
	/s/	 	 
	Secretary	 	 

 

	
         

 

 

 

    	13EXHIBIT 10.02

 

 

Contribution Agreement 

BETWEEN 

ROSELLINI SCIENTIFIC LLC
AND NEXEON MEDSYSTEMS INC.

 

 

This 2015 Contribution
Agreement (the “Agreement”), dated as of January 2, 2016, by and between Rosellini Scientific LLC, a Texas limited
liability company and Belltower Associates LLC, a Delaware limited liability company, a wholly owned subsidiary of Rosellini Scitenific
LLC, (collectively the “Transferor”), and Nexeon MedSystems Inc, a Nevada corporation (the “Transferee”).

 

WHEREAS, Transferor entered
into a Joint Venture Agreement with Nexeon MedSystems Inc, a Delaware corporation, (“NMD”) predecessor to Transferee;
and

 

WHEREAS, Transferee has
entered into a merger acquisition agreement with NMD whereby Transferee will become the successor corporation and NMD will be dissolved;
and

 

WHEREAS, Transferor owns
various valuable tangible and intangible assets it wishes to contribute to Transferee in exchange for shares of Transferee’s
Restricted Common Stock representing a controlling interest in Transferee; and

 

WHEREAS, Transferor and
Transferee now wish to enter into this Contribution Agreement whereby Transferor contributes the assets set forth herein below
in exchange for 13,200,000 shares of Transferee’s Restricted Common Stock (the “Stock”);

 

NOW, THEREFORE, in consideration
of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.       Contributions and Services. Transferor hereby contributes and in addition shall provide various services to
Transferee and hereby transfers all if its rights, title, copyright, and interests of any kind or nature whatsoever in and to any
and all of the following:

 

		a.	Transferor shall provide an experienced management team in order to advance the development and
commercialization of the medical intellectual property currently owned or controlled by the Transferee or acquired as a result
of its merger with NMD;

 

		b.	Transferor, during 2016, shall organize and file, on behalf of Transferee, a Form 10 Registration
Statement with the U.S. Securities and Exchange Commission in order for the Transferee to become a full reporting public company
trading on the OTC Markets QB Stock Exchange. In the near future it will be the intent of Transferor to file an N-2 Statement pursuant
to the 1940 Investment Company Act and transform Transferee into an SEC Registered Business Development Corporation;

 

		c.	Transferor shall use its best efforts to assist Transferee and NMD with the conversion of any and
all of Transferee’s accounts payable to a paid status using cash and shares of Transferee’s Restricted Common Stock;

 

		d.	Transferor shall use its best efforts to assist Transferee and NMD with the conversion of any and
all of Transferee’s stockholder loans;

 

    	1

    	 

    

 

		e.	Transferor shall cause to be prepared and circulate an SEC Regulation D Private Placement Memorandum
and use its best efforts to form up to $1,000,000 of new capital for Transferee prior to the end of the second quarter 2016;

 

		f.	Transferor shall assign, subject to regulatory transfer approval, all rights, title, and interest
in and to the Federal NIH/SBIR awarded Grant #1R44HL129870-01 described n section (a) below. In addition Transferor, upon award,
shall assign, subject to regulatory transfer approval, all rights, title, and interest to Transferee in and to the following Federal
Grants:

 

(a)     1R44HL129870-01 Development of a microperforated nanocomposite balloon for intravascular anti-restenotic drug delivery; 

 

(b)     1R43CA206792-01 Localized, Intravascular Delivery of TALE Fusion Proteins for Hepatocellular Carcinoma BATES, MARK  Pending
IRG Review 9/16/2015

 

(c)     1R43CA206773-01 Deployable Filter for the Capture of Embolic Bead Reflux BATES, MARK  Pending IRG Review 9/15/2015;

 

(d)     1R43HL131214-01A1 Development of a sheath with a deployable filter system for intravascular embolism protection to reduce
occlusions that can eventually require extremity amputation. BATES, MARK  Pending IRG Review 9/14/2015;

 

		g.	Transferor shall assign, subject to regulatory transfer approval, all of its rights, title, and
interest in and to the Matching Funds Grant #KSTC-184-512-16-234 in the amount of $150,000 awarded by the State of Kentucky;

 

		h.	Transferor hereby assigns all of its rights, title, and interest in and to the Joint Venture Agreement,
dated March 3, 2015 by and between Transferor and NMD;

 

		i.	Transferor hereby assigns and transfers all of its rights, title, and interest in and to 1,675,000
shares of Nuviant Medical Inc, a Nevada corporation, Restricted Common Stock;

 

		j.	Transferor hereby assigns and transfers all of its rights, title, and interest in and to 167 shares
of Microtransponder, Inc., a Delaware corporation, Restricted Common Stock;

 

		k.	140 Shares of Common Stock of Telemend Medical, Inc., a Deleware corporation, along with a five
year promissory note with annual interest at the rate of 8% payable to Rosellini Scientific LLC by Telemend Medical, Inc.

 

		l.	Transferor herby grants the exclusive option to Transferee, to be exercised no later than September
31, 2016, to acquire from Transferor all of the shares of Restricted Common Stock or Membership Interest owned or controlled by
Transferor on the date at which Transferee exercises its option to acquire such interest of NeuroTek Medical, Inc., a Delaware
corporation. There shall be no additional consideration payable from Transferee to Transferor upon the exercise of such option(s)
by Transferee; and

 

    	2

    	 

    

 

		m.	Any
and all assets set forth herein above are being transferred by Transferor to Transferee at the then current tax basis as set forth
in the books and records of Transferor.

 

2.     Representations
and Warranties of Transferee. Transferee hereby represents and warrants to Transferor, that the statements in the following
paragraphs of this Section 2 are all true, correct, and complete as of the date of execution hereof:

 

a.     Due Organization;
Good Standing and Power. The Transferee is duly organized corporation, validly existing and, in good standing under the laws
of Nevada. The Transferee has the corporate power and authority to own, lease, and operate its assets and to conduct its Business
as presently being conducted.

 

b.     Validity of Agreement;
Capitalization. Transferee has the full power and authority to enter into this Agreement to which it is a party and to consummate
the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by the Transferee and this
Agreement constitutes a legal, valid and binding obligation of the Transferee, enforceable against it in accordance with its terms,
except as the same may be limited by bankruptcy, insolvency or other similar laws affecting creditors' rights generally and by
general equity principles. The execution, delivery and performance of this Agreement to which it is a party by the Transferee has
been duly authorized by all requisite corporate action on its part.

 

c.     No Approvals or
Notices Required; No Conflict with Instruments. The execution, delivery and performance of this Agreement by the Transferee
and the consummation by it of the transactions contemplated hereby (i) does not violate (with or without the giving of notice or
the lapse of time or both) or require any consent, approval, filing or notice under, (ii) does not result in the creation of any
Encumbrance (except pursuant to this Agreement and those arising by virtue of any action taken by or on behalf of Transferor or
its affiliates and restrictions on transfers that may be imposed by Applicable Laws) on the Transferee Stock or any equity interests
of the Transferee under, conflict with, or result in the breach or termination of any provision of, or constitute a default under,
or result in the acceleration of the performance of the obligations of the Transferee under, or (iii) result in the creation of
an encumbrance upon any asset of the Transferee pursuant to: (A) applicable law, (B) any permit, (C) the limited liability charters
or bylaws of the Transferee, or (D) any instrument or other agreement to which the Transferee is a party or by which any of its
assets are bound or affected. The newly issued restricted shares of the Transferee’s Common Stock are transferable and assignable
to Transferor as contemplated by this Agreement without the waiver of any right of first refusal or the consent of any other party
being obtained, and there exists no preferential right of purchase in favor of any person with respect of any of the Transferee
Stock or the business.

 

d.     Legal Proceedings.
There is no litigation, proceeding, claim or governmental investigation pending or, to the knowledge of the Transferee, threatened,
that seeks relief or damages against the Transferee or any of the respective assets or the business or which would prevent the
consummation of the transactions contemplated by this Agreement and the Transferee has not been charged with any violation of or,
to the knowledge of the Transferee, threatened with a charge or violation of, any provision of applicable laws.

 

    	3

    	 

    

 

e.     Conduct of Business
in Compliance with Applicable Laws. The Transferee has conducted its Business in compliance with all Applicable Laws, except
as would not, individually or in the aggregate, have a material adverse effect.

 

f.     Certain Fees.
Neither the Transferee nor its respective officers, directors or employees, have employed any broker or finder or incurred any
other liability for any brokerage fees, commissions or finders' fees in connection with the transactions contemplated hereby.

 

g.     No Other Representations
Acknowledgement. The Transferee acknowledges that neither the Transferor nor any of their affiliates or any of their respective
directors, officers, employees, agents, advisors or representatives makes any representation or warranty, either express or implied,
to the Transferee or their agents or representatives, except for the representations and warranties set forth in this Agreement,
or in any certificate or other instrument or document delivered in connection herewith or therewith.

 

3.     Representations and Warranties of
Transferor. Transferor hereby represents and warrants to the Transferee that the statements in the following paragraphs
of this Section 3 are all true and complete as of the Payment Date:

 

Due Organization; Good Standing and Power.
The Transferor is duly organized limited liability company, validly existing and in good standing under the laws of Texas. The
Transferee has the corporate power and authority to own, lease, and operate its assets and to conduct its Business as presently
being conducted.

 

Exempt Transaction. Transferor understands
that the offering and sale of the newly issued restricted shares of the Transferee’s Restricted Common Stock is intended
to be exempt from registration under the Securities Act and exempt from registration or qualification under any state law.

 

b.     Full Power and Authority.
Transferor represents that they have full power and authority to enter into this Agreement and consummating the transactions contemplated
hereby.

 

c.     The Newly Issued
Restricted Shares The newly issued shares of the Transferee’s Restricted Common Stock to be acquired by Transferor hereunder
will be acquired for investment for Transferor’s own account, not as a nominee or agent, and not with a view to the public
resale or distribution thereof, and Transferor has no present intention of selling, granting any participation in, or otherwise
distributing the same except within the terms, conditions, restrictions, and rules of the United States Securities and Exchange
Commission.

 

d.     Investment Experience.
Transferor understands that the receipt of the newly issued shares of the Transferee’s Restricted Common Stock involves
substantial risk. Transferor:

 

i.     has experience as
an acquirer and owner of securities of companies in the development stage and acknowledges that it can bear the economic risk of
Transferor’s investment in Transferee’s Restricted Common Stock; and,

 

ii.     has such knowledge
and experience in financial, tax, and business matters so as to enable Transferor to evaluate the merits and risks of an investment
in Transferee’s Restricted Common Stock, to protect Transferor’s own interests in connection with the acquisition and
to make an informed investment decision with respect thereto.

 

    	4

    	 

    

 

e.     No Oral Representations.
No oral or written representations have been made other than or in addition to those stated in this Agreement. Transferor is not
relying on any oral or written statements made by the Transferee, Transferee’s agent, representatives, employees or affiliates
in acquiring Transferee’s Restricted Common Stock.

 

f.     Restricted Securities.
Transferor understands that the Transferee’s Restricted Common Stock is characterized as "restricted securities"
under the Securities Act in as much as they are being acquired by the Transferor from the Transferee in a transaction not involving
a public offering.

 

g.     Opinion Necessary.
Transferor acknowledges that if any transfer of the Transferable Transferee’s Restricted Common Stock is proposed to
be made in reliance upon an exemption under the Securities Act, the Transferee may require an opinion of counsel that such transfer
may be made pursuant to an applicable exemption under the Securities Act. Transferor acknowledges that a restrictive legend will
appear on Transferee’s Restricted Common Stock and must remain until such time as it may be removed under the Securities
Act.

 

h.     Information. Transferor
hereby acknowledges the receipt of any and all information regarding the Transferee including financial statements requested by
Transferor or its officers, directors, employees or agents as that information is received.

 

4.     Indemnification.

 

a.     Transferee shall indemnify
and hold harmless the Transferor from and against any and all losses, damages, expenses and liabilities (collectively "Liabilities")
or actions, investigations, inquiries, arbitrations, claims or other proceedings in respect thereof, including enforcement of this
Agreement (collectively "Actions" and together with the Liabilities, the "Losses") arising out of or in connection
with the conduct of Transferee. Losses include, but are not limited to, all reasonable legal fees, court costs and other expenses
incurred in court costs and other expenses incurred in connection with investigating, preparing, defending paying, settling or
compromising any suit in law or equity arising out of this Agreement or for any breach of this Agreement notwithstanding the absence
of a final determination as to Transferor’s obligation to reimburse Transferee for such losses and the possibility that such
payments might later be held to have been improper. connection with investigating, preparing, defending, paying, settling or compromising
any suit in law or equity arising out of this Agreement or for any breach of this Agreement notwithstanding the absence of a final
determination as to a Transferee's obligation to reimburse Transferor for such Losses and the possibility that such payments might
later be held to have been improper.

 

b.     Transferor shall indemnify
and hold harmless the Transferee from and against any and all losses, damages, expenses and liabilities or actions, investigations,
inquiries, arbitrations, claims or other proceedings in respect thereof, including enforcement of this Agreement arising out of
or in connection with the conduct of Transferor. Losses include, but are not limited to, all reasonable legal fees,

 

5.     Conditions
Precedent. The obligations of Transferor set forth in Section 1 herein above shall be conditioned upon the occurrence of
the following events: 1) Shareholder’s of Transferee holding debt owed by Transferee shall have agreed to convert said debt
to cash and shares of restricted common stock of Transferee in satisfaction of all debt; 2) NMD and Transferee shall have entered
into a binding definitive merger agreement whereby any and all terms and conditions of said agreement, precedent other otherwise
shall have been met and the merger transaction is ready for final completion.

 

    	5

    	 

    

 

6.     Transferee
Board of Directors. Simultaneous with the transfer of Transferee’s shares of Restricted Common Stock to Transferor
the member(s) of Transferee’s Board of Directors shall elect William Rosellini, Mark Bates, and an individual nominated by
Mark Bates, and an individual nominated by William Rosellini to the Board of Directors of Transferee and each existing member of
the Board, except for Ron Conquest, shall resign.

 

7.     Further
Assurances. Transferor and Transferee agree to execute any and all documents and instruments of transfer, assignment, assumption
or novation and to perform such other acts as may be reasonably necessary or expedient to further the purposes of this Agreement
and the transactions contemplated by this Agreement.

 

8.     Entire
Agreement. This Agreement constitutes the sole and entire agreement of the parties to this Agreement with respect to the
subject matter contained herein, and supersedes all prior and contemporaneous understandings, representations and warranties and
agreements, both written and oral, with respect to such subject matter.

 

9.     Successors
and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns.

 

10.   No
Third-Party Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their respective successors
and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person any legal or
equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement.

 

11.   Headings.
The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

12.   Amendment
and Modification; Waiver. This Agreement may only be amended, modified or supplemented by an agreement in writing signed
by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in
writing and signed by the party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in
exercising, any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof;
nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise
thereof or the exercise of any other right, remedy, power or privilege.

 

13.   Governing
Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without
giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that
would cause the application of Laws of any jurisdiction other than those of the State of Nevada.

 

14.   Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed
to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

    	6

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Second Amended and Final Contribution Agreement to be effective as of the date first above
written herein.

 

	ROSELLINI
                                         SCIENTIFIC LLC 
	 	
	 	 	 	 
	 	 	 	 
	By:	/s/
    William Rosellini	 	Date: January 2, 2016
	 	William Rosellini, Its Sole Member	 	

 

 

	NEXEON MEDSYSTEMS Inc.	 	
	 	 	 	 
	 	 	 	 
	By:	/s/
    Ron Conquest	 	Date: January 2, 2016
	 	Ron Conquest, Sole Director and Shareholder	 	

 

 

 

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]